Middle East Healthcare Company Stocks

SAR 38.6Last Updated 27.04.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

SAR 966.86M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
SAR 38.6
Key Takeaways

Risk factor

Resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Middle East Healthcare Company, a healthcare provider, owns and operates a network of hospitals under the Saudi German Hospital name in the Middle East and North Africa. The company operates multi-specialty tertiary level hospitals, which comprise Saudi German Hospital–Jeddah with 218 beds; Saudi German Hospital-Aseer with 400 beds; Saudi German Hospital-Riyadh with 300 beds; Saudi German Hospital-Madinah with 300 beds; and Saudi German Hospital-Hail with 150 beds. Its multi-specialty tertiary care hospitals also include Saudi German Hospital-Dammam with 150 to 300 beds; Saudi German Hospital-Sanaa with 300 beds; Saudi German Hospital–Dubai with 300 beds; Saudi German Hospital–Sharjah with 50 beds; Saudi German Hospital–Ajman with 100-200 beds; and Saudi German Hospital-Cairo with 332 beds. The company was founded in 1988 and is based in Jeddah, the Kingdom of Saudi Arabia.

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITDA

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of 4009.SR is 67 and suggests 74% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks